Sign In
Buy PCVX
$51.96
-0.150 (-0.288%)
At Close: Jun 23, 2026
Why Shares of Vaxcyte Rose 110.7% This Week
11:03am, Saturday, 29'th Oct 2022
The company released early data for a promising pneumonia vaccine.
Recent Price Trend in Vaxcyte, Inc. (PCVX) is Your Friend, Here's Why
10:32am, Tuesday, 25'th Oct 2022
Vaxcyte, Inc. (PCVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it throug
Why Is Vaxcyte (PCVX) Stock Up 70% Today?
11:00am, Monday, 24'th Oct 2022
Vaxcyte (NASDAQ: PCVX ) stock is rocketing higher on Monday after the vaccine company revealed positive data from a Phase 1/2 clinical trial. This part of the study handled the safety, tolerability, a
Why Is Vaxcyte (PCVX) Stock Up 70% Today?
10:59am, Monday, 24'th Oct 2022
Vaxcyte (NASDAQ: PCVX ) stock is rocketing higher on Monday after the vaccine company revealed positive data from a Phase 1/2 clinical trial. This part of the study handled the safety, tolerability, a
Vaxcyte's stock rallies 46% on positive data for its pneumococcal vaccine candidate
07:52am, Monday, 24'th Oct 2022
Shares of Vaxcyte Inc. PCVX, -7.42% soared 46.7% in premarket trading on Monday after the company said its experimental 24-valent pneumococcal conjugate vaccine met the primary endpoint in a Phase 1/2
SAN CARLOS, Calif., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Vaxcyte to Present at the Jefferies Healthcare Conference
04:05pm, Thursday, 02'nd Jun 2022
SAN CARLOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Vaxcyte to Participate in Upcoming Investor Conferences in May
08:30am, Tuesday, 03'rd May 2022
SAN CARLOS, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseque
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
08:30am, Tuesday, 05'th Apr 2022
SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq
Vaxcyte, Inc. (PCVX) CEO Grant Pickering on Q4 2021 Results - Earnings Call Transcript
08:05pm, Monday, 28'th Feb 2022
Vaxcyte, Inc. (PCVX) CEO Grant Pickering on Q4 2021 Results - Earnings Call Transcript
Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
08:30am, Thursday, 17'th Feb 2022
SAN CARLOS, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacter
Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference
08:30am, Thursday, 10'th Feb 2022
SAN CARLOS, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacter
Vaxcyte Stock (PCVX): Why The Price Went Down
02:59am, Friday, 14'th Jan 2022
The stock price of Vaxcyte Inc (NASDAQ: PCVX) fell by 9.5% in the most recent trading session. This is why it happened.
Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate
12:09pm, Thursday, 13'th Jan 2022 Benzinga
Vaxcyte Inc (NASDAQ: PCVX ) priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share, respectively. Vaxcyte is selling 2.5 million shares and pre-funded warrants to purchase 2.5 million shares of common stock in the offering. The aggregate gross proceeds to Full story available on Benzinga.com
Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate
07:09am, Thursday, 13'th Jan 2022
Vaxcyte Inc (NASDAQ: PCVX) priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share, respectively. Vaxcyte is selling 2
